Trials / Recruiting
RecruitingNCT06067698
Alpha Lipoic Acid in Ulcerative Colitis
Clinical Study Evaluating the Efficacy and Safety of Alpha-lipoic Acid in Patients With Ulcerative Colitis Treated With Mesalamine
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Tanta University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims at evaluating the efficacy and safety of alpha-lipoic acid as adjuvant therapy to mesalamine in patients with mild to moderate ulcerative colitis due to its effect as anti-oxidant and anti-inflammatory drug which can help to improve disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | "Mesalamine" and "alpha-lipoic acid" | Mesalamine 1000 mg every 8 hrs. + alpha-lipoic acid 600 mg once daily for 3 months |
| DRUG | "Mesalamine" and "Placebo" | Mesalamine 1000 mg every 8 hrs. + Placebo once daily for 3 months |
Timeline
- Start date
- 2023-10-01
- Primary completion
- 2025-04-01
- Completion
- 2025-04-01
- First posted
- 2023-10-05
- Last updated
- 2025-02-06
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT06067698. Inclusion in this directory is not an endorsement.